ANNX - NASDAQ
Annexon, Inc.
$5.39
+2.5%Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
At a Glance
Live SnapshotNo Revenue Data
ANNX has not reported any revenue values in the available annual periods.
Annexon, Inc. Profit Bridge
Profitability Analysis
Annexon, Inc. Income Statement
ANNX • NASDAQ
| Annexon, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
GROSS PROFIT | |||||||||
(3.7M) | (3.5M) | (0.0) | (0.0) | (0.0) | (0.0) | (493K) | (488K) | (271K) | |
-3.7M | -3.5M | 0.0 | 0.0 | 0.0 | 0.0 | -493K | -488K | -271K | |
OPERATING INCOME | |||||||||
(212.7M) | (150.6M) | (143.7M) | (145.6M) | (130.7M) | (63.5M) | (32.5M) | (19.1M) | (20.2M) | |
(31.7M) | (34.6M) | (28M) | (30.9M) | (30.6M) | (14.2M) | (8M) | (3.6M) | (2.4M) | |
(184.7M) | (119.4M) | (113.8M) | (112.5M) | (100.1M) | (49.3M) | (24.5M) | (15.5M) | (17.9M) | |
-216.4M | -154.1M | -143.7M | -145.6M | -130.7M | -63.5M | -32.5M | -19.1M | -20.5M | |
PRE-TAX INCOME | |||||||||
9.7M | 0.0 | 9.5M | 3.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-3.7M | -3.5M | (1.9M) | (2.2M) | (0.0) | (0.0) | -4.7M | (844K) | (0.0) | |
9.7M | 15.9M | 9.5M | 3.7M | 390K | 57K | -4.7M | 844K | 1.8M | |
-206.7M | -138.2M | -134.2M | -141.9M | -130.3M | -63.4M | -37.2M | -18.3M | -18.7M | |
NET INCOME | |||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (4K) | (1K) | (1K) | |
-206.7M | -138.2M | -134.2M | -141.9M | -130.3M | -63.4M | -37.2M | -18.3M | -18.7M |
SEC Filings
ANNX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 14, 2026 | January 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your ANNX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.